Stay updated on Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.
Latest updates to the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedMelanoma and related topics were removed from the page content. This reduces disease-specific context and related resource links on the study page.SummaryDifference0.1%
- Check20 days agoChange DetectedThe Publications section wording has been updated to indicate PubMed publications are auto-filled and may not all pertain to the study, and the revision banner shows Revision: v3.3.2 (from v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check27 days agoChange DetectedA funding/operating status notice was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check49 days agoChange DetectedOnly minor visual/layout adjustments were observed; no core study information such as the title, brief summary, inclusion/exclusion criteria, endpoints, or locations appears to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check70 days agoChange DetectedUpgrade to version v3.2.0 with a new government-operating-status notice and links; removes the old v3.1.0 reference.SummaryDifference2%
- Check77 days agoChange DetectedAdded Melanoma genetics topic and updated version from v3.0.2 to v3.1.0.SummaryDifference0.2%
Stay in the know with updates to Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.